| mechanism of S100A8 in the oncogenesis and development of laryngeal cancer | laryngeal, |
| Helicobacter pylori exploits host membrane phosphatidylserine for delivery, localization, and pathophysiological action of the CagA oncoprotein. | liver, |
| Helicobacter pylori CagA targets gastric tumor suppressor RUNX3 for proteasome-mediated degradation. | gastric, |
| [H. pylori oncoprotein CagA and gastric cancer]. | gastric, |
| Pathophysiological functions of the CagA oncoprotein during infection by Helicobacter pylori. | None |
| Attenuated CagA oncoprotein in Helicobacter pylori from Amerindians in Peruvian Amazon. | None |
| Evolution of cagA oncogene of Helicobacter pylori through recombination. | None |
| Tertiary structure-function analysis reveals the pathogenic signaling potentiation mechanism of Helicobacter pylori oncogenic effector CagA. | None |
| Structural insights into Helicobacter pylori oncoprotein CagA interaction with beta1 integrin. | None |
| [Structure and mode of injection of the oncoprotein CagA of Helicobacter pylori]. | None |
| Characterization of the translocation-competent complex between the Helicobacter pylori oncogenic protein CagA and the accessory protein CagF. | None |
| Natural variant of the Helicobacter pylori CagA oncoprotein that lost the ability to interact with PAR1. | None |
| Perturbation of PAR1b and SHP2 by CagA underlies the oncogenic potential of CagA. | None |
| Structure of the Helicobacter pylori CagA oncoprotein bound to the human tumor suppressor ASPP2. | None |
| [Study of infection strategies of Helicobacter pylori and host cell response against CagA oncoprotein]. | None |
| In Silico Profiling of the Potentiality of Curcumin and Conventional Drugs for CagA Oncoprotein Inactivation. | None |